Alnylam's (ALNY) Strong ALN-PCSsc Data at AHA Conference, FBR Capital Notes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LMT
8. USO
9. META
10. TLT

Go back to Alnylam's (ALNY) Strong ALN-PCSsc Data at AHA Conference, FBR Capital Notes

Medicines Co. (MDCO), Alnylam' (ALNY) ALN-PCSsc Data Affirm Potential bi-Annual Dose Regimen - Chardan Capital

November 11, 2015 12:35 PM EST

Chardan Capital affirms Medicines Company (Nasdaq: MDCO) with a Buy rating and $50 price target after the company and Alnylam (Nasdaq: ALNY)... More

Alnylam Pharma (ALNY), Medicines Co. (MDCO) Announce Positive Data from Ongoing ALN-PCSsc Phase 1

November 11, 2015 10:47 AM EST

Alnylam Pharma (NASDAQ: ALNY) and The Medicines Company (Nasdaq: MDCO) reported positive results from their ongoing Phase 1 clinical trial with ALN-PCSsc in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2015.

ALN-PCSsc is an investigational RNAi therapeutic... More

Medicines (MDCO)/Alnylam (ALNY) to Present Phase 1 Data on siRNA-based PCSK9 Today

November 11, 2015 8:23 AM EST

Evercore ISI analyst Umer Raffat notes Medicines Co. (NASDAQ: MDCO)/Alnylam Pharma (NASDAQ: ALNY) will present updated Ph 1 data on their siRNA-based PCSK9 at AHA late breaker today/

Below are key things Raffat is... More